Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Medpace (MEDP)

Medpace Q2 revenue rises 17.2% to $707.3 million; diluted EPS $4.25

Positive Impact 3 of 5 earnings Written later

Medpace reported second quarter 2026 revenue of $707.3 million, up 17.2% from a year earlier, and GAAP net income of $121.4 million, or $4.25 per diluted share, compared with $3.10 a year earlier. The company also forecast full-year 2026 revenue of $2.805 billion to $2.885 billion and diluted EPS of $17.25 to $17.95.

Key points

  • Q2 2026 revenue $707.3 million, up 17.2% from $603.3 million in Q2 2025
  • Q2 2026 GAAP net income $121.4 million ($4.25 diluted EPS) vs. $90.3 million ($3.10) a year earlier
  • Q2 2026 net new business awards $795.7 million, up 28.2%; book-to-bill ratio 1.13x
  • Full-year 2026 guidance: revenue $2.805 billion to $2.885 billion; GAAP net income $494.0 million to $514.0 million

The filing

CompanyMedpace (MEDP)
Form8-K, current report
Filed with the SECJul 22, 2026, 4:15 PM ET
Accession number0001668397-26-000023

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.